Investment thesis

1. Addressing large markets with significant patient needs:

Focusing on becoming a leader within the large and growing space of addiction, alongside addressing the opioid epidemic, one of the largest health crises ever in America and a growing global concern

2. Strong financial position and profitability:

Fueled by the sales of the lead product Zubsolv® which will continue to be an important cash and profitability contributor

3. Leverage the US ­commercial platform:

Strategic focus on product portfolio expansion, through M&A and business development, to leverage the US commercial infrastructure

4. Expanding pipeline:

Continues to build on the strong track record of developing products with worldwide approval by expanding the pipeline with multiple assets based on innovative drug delivery technologies and digital therapies addressing unmet medical need in addiction

5. Entering digital therapeutics, the new mega­trend in life science:

Digital therapeutics will become an integral part of the healthcare landscape and addiction is one of the therapeutic areas where it is most needed